published meta-analysis   sensitivity analysis   studies

first booster dose in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsArbel, 2021 0.10 [0.07; 0.14] Barda, 2021 0.19 [0.05; 0.70] McConeghy, 2022 0.03 [0.01; 0.10] 0.09[0.04; 0.19]Arbel, 2021, Barda, 2021, McConeghy, 2022355%843,208moderatenot evaluable hospitalization or deathdetailed resultsAbu-Raddad, 2022 0.23 [0.12; 0.44] McConeghy, 2022 0.54 [0.23; 1.26] 0.34[0.15; 0.77]Abu-Raddad, 2022, McConeghy, 2022259%NAnot evaluable confirmed COVID (any severity)detailed resultsAbu-Raddad, 2022 0.51 [0.49; 0.54] Accorsi, 2022 0.35 [0.33; 0.38] Bar-On, 2021 0.09 [0.08; 0.10] C4591031- first boost, 2021 0.05 [0.02; 0.13] COVI3, 2022 0.07 [0.02; 0.22] Kislaya, 2022 0.31 [0.18; 0.54] Mattiuzzi, 2022 0.35 [0.32; 0.38] McConeghy, 2022 0.49 [0.34; 0.70] Patalon, 2021 0.21 [0.16; 0.28] Patalon, 2022 0.15 [0.14; 0.17] Tan, 2022 0.27 [0.26; 0.29] 0.23[0.16; 0.32]Abu-Raddad, 2022, Accorsi, 2022, Bar-On, 2021, C4591031- first boost, 2021, COVI3, 2022, Kislaya, 2022, Mattiuzzi, 2022, McConeghy, 2022, Patalon, 2021, Patalon, 2022, Tan, 20221199%10,125NAlow hospitalizationdetailed resultsBarda, 2021 0.07 [0.04; 0.14] Lauring, 2022 0.06 [0.05; 0.08] Mattiuzzi, 2022 0.31 [0.22; 0.44] McConeghy, 2022 0.52 [0.08; 3.59] Patalon, 2022 0.08 [0.05; 0.13] Tan, 2022 0.05 [0.03; 0.08] Tenforde, 2022 0.18 [0.09; 0.35] 0.11[0.06; 0.21]Barda, 2021, Lauring, 2022, Mattiuzzi, 2022, McConeghy, 2022, Patalon, 2022, Tan, 2022, Tenforde, 2022792%398,920NAnot evaluable symptomatic Covid-19detailed resultsAbu-Raddad, 2022 0.53 [0.47; 0.59] Accorsi, 2022 0.35 [0.33; 0.38] COVI3, 2022 0.07 [0.02; 0.25] 0.37[0.24; 0.56]Abu-Raddad, 2022, Accorsi, 2022, COVI3, 2022395%NAnot evaluable ICU admissiondetailed resultsMattiuzzi, 2022 0.33 [0.08; 1.36] 0.33[0.08; 1.36]Mattiuzzi, 202210%NAnot evaluable severe COVID-19 (FDA definition)detailed resultsC4591031- first boost, 2021 0.25 [0.01; 5.50] 0.25[0.01; 5.50]C4591031- first boost, 202110%10,125NAnot evaluable severe COVID-19 occurrencedetailed resultsBar-On, 2021 0.06 [0.04; 0.10] Barda, 2021 0.08 [0.03; 0.20] C4591031- first boost, 2021 0.25 [0.01; 5.50] Tan, 2022 0.05 [0.03; 0.08] 0.06[0.05; 0.08]Bar-On, 2021, Barda, 2021, C4591031- first boost, 2021, Tan, 202240%10,125NAnot evaluable arrhythmiadetailed resultsC4591031- first boost, 2021 1.99 [0.07; 59.22] 1.99[0.07; 59.22]C4591031- first boost, 202110%10,075NAnot evaluable hypertensiondetailed resultsC4591031- first boost, 2021 0.50 [0.02; 14.80] 0.50[0.02; 14.80]C4591031- first boost, 202110%10,075NAnot evaluable Myocardial infarction detailed resultsC4591031- first boost, 2021 0.74 [0.17; 3.33] 0.74[0.17; 3.33]C4591031- first boost, 202110%10,075NAnot evaluable pulmonary embolismdetailed resultsC4591031- first boost, 2021 0.17 [0.01; 3.30] 0.17[0.01; 3.30]C4591031- first boost, 202110%10,075NAnot evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed resultsC4591031- first boost, 2021 0.99 [0.06; 15.88] 0.99[0.06; 15.88]C4591031- first boost, 202110%10,075NAnot evaluable cerebral venous sinus thrombosis (CVST)detailed resultsC4591031- first boost, 2021 0.50 [0.02; 14.80] 0.50[0.02; 14.80]C4591031- first boost, 202110%10,075NAnot evaluable appendicitisdetailed resultsC4591031- first boost, 2021 3.97 [0.18; 88.14] 3.97[0.18; 88.14]C4591031- first boost, 202110%10,075NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-04-28 13:20 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 1088,1331,1330,1329,1344,1328,1327 - roots T: 290